industry
November 20, 20266 min readDRMED Quality & Compliance

Health Technology Assessment: How It Differs From Approval

A medical device can clear every regulatory hurdle in its target market and still sit on a shelf because no payer or hospital system is willing to fund it. That gap is not a failure of the regulatory process. It reflects the fact that regulatory approval and Health Technology Assessment (HTA) are two separate evaluations, run by different bodies, asking different questions, on different timelines. For distributors and procurement teams, understanding where one ends and the other begins is essential to reading market access correctly.

Two Gatekeepers, Two Different Questions

Regulatory approval, whether that is CE marking under the EU Medical Device Regulation or a clearance pathway elsewhere, asks a narrow question: does this product meet defined safety, performance and quality requirements well enough to be legally placed on the market? HTA asks a broader and more comparative question: given that the product is approved, how well does it perform against the alternatives already available, and is the added clinical benefit, if any, worth the added cost? A product can pass the first test and still face a difficult answer to the second.

What Regulatory Dossiers Actually Establish

A regulatory submission is built around a defined evidence threshold: that the device performs as intended and that its risks are acceptable relative to its intended benefit, as documented in a clinical evaluation. It does not require the manufacturer to show that the product is better than, or more cost-effective than, a competing product or an existing standard of care. Two devices treating the same condition can both be legitimately approved while performing very differently on cost or on comparative outcomes, because approval was never designed to rank them against each other.

What HTA Adds: Comparative and Economic Evidence

HTA bodies, such as national agencies that advise on reimbursement and formulary decisions, evaluate comparative effectiveness (how the product performs against existing alternatives, not against a placebo alone) and cost-effectiveness (the clinical benefit gained relative to the additional cost). This typically draws on randomized trial data where available, supplemented increasingly by real-world evidence collected after launch. The output of an HTA review is not a market authorization. It is a recommendation or decision that shapes whether, and at what price, a national or regional payer will fund the product.

Why the Two Processes Rarely Move in Step

Regulatory review happens once, ahead of market entry, against a largely fixed evidence standard. HTA is typically national or regional, can be repeated market by market, and its evidence bar often keeps moving as comparators change and new data accumulates. A product can be approved for years in a given market before an HTA body revisits its reimbursement status in light of a newer competing technology. This is why a CE mark or equivalent clearance should be read by buyers as a safety and performance floor, not as a signal about reimbursement, pricing or local formulary status.

Europe's Move Toward Shared Clinical Assessment

The EU has been working to reduce duplication across member states by coordinating parts of the HTA process at a European level, so that a joint clinical assessment produced once can feed into multiple national decisions rather than each country repeating the same comparative-evidence review from scratch. This coordination is being phased in gradually, starting with a defined set of product categories, while the remaining scope and timeline for other categories, including most medical devices, continues to expand over time. Distributors should expect national HTA bodies to remain the primary decision-makers on pricing and reimbursement for the foreseeable future, with European-level coordination acting as an input rather than a replacement.

The Takeaway

Regulatory approval and Health Technology Assessment protect against different failure modes: one against an unsafe or poorly performing product reaching the market, the other against public or insurer funds being spent on a product that adds little value relative to its cost. A distributor preparing to enter a new market should budget for both tracks separately, with distinct evidence packages, distinct timelines and, often, distinct local partners, rather than assuming a regulatory approval already answers the reimbursement question.

This is general educational information, not legal or regulatory advice; consult the current official texts and your competent authority.